Skip to main content

Table 1 Patients characteristics

From: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

No. of patients

27

Median age [range], years

61.4 [47.6 - 74.1]

Gender

 

Male

15 (55.6%)

Female

12 (44.4%)

ECOG performance status score

 

0

5 (18.5%)

1

7 (25.9%)

2

9 (33.3%)

3

3 (11.1%)

Unknown

3 (11.1%)

First line chemotherapy

 

FOLFIRI.3 alternating with Gemcitabine

7 (25.9%)

Gemcitabine

20 (74.1%)

Pancreatic tumor location

 

Head

14 (51.8%)

Body

6 (22.2%)

Tail

6 (22.2%)

Multicentric

1 (3.7%)

Metastatic sites

 

Liver

20 (74.1%)

Peritoneum

8 (29.6%)

Lung

6 (22.2%)

Distant lymph nodes

2 (7.4%)

No. of metastatic sites involved

 

1

19 (70.4%)

2

7 (25.9%)

≥ 3

1 (3.7%)

Baseline CA 19–9 level

 

≤ 37 UI/ml*

2 (7.4%)

> 37 UI/ml

19 (70.4%)

Unknown

6 (22.2%)

No. of cycle

 

Mean

6

Median [range]

4 [1–28]

  1. Abbrevations: ECOG Eastern Cooperative Oncology Group;
  2. *upper limit of normal value.